Daveen Chopra - 03 May 2022 Form 4 Insider Report for Edwards Lifesciences Corp (EW)

Role
CVP, Surgical Structural Heart
Signature
Linda J. Park, Attorney-in-Fact
Issuer symbol
EW
Transactions as of
03 May 2022
Net transactions value
-$29,554
Form type
4
Filing time
05 May 2022, 17:51:30 UTC
Previous filing
14 Jun 2021
Next filing
10 May 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction EW Common Stock Award $0 +3,250 +21% $0.000000 19,077 03 May 2022 Direct F1
transaction EW Common Stock Tax liability $29,554 -279 -1.5% $105.93 18,798 04 May 2022 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction EW Employee Stock Option (Right to Acquire) Award $0 +26,400 $0.000000 26,400 03 May 2022 Common Stock 26,400 $105.93 Direct F2
transaction EW Performance Rights Award $0 +4,075 $0.000000 4,075 03 May 2022 Common Stock 4,075 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These restricted stock units were granted on May 3, 2022 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments.
F2 These options were granted on May 3, 2022 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments.
F3 Reflects the target number of shares (the Target Award) covered by restricted stock units granted on May 3, 2022 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and scheduled to vest on May 3, 2025. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards.

Remarks:

This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person.